Further modification of KG6E was done by conjugating an anti-mucin 1 (MUC1) aptamer by Masuda et al. in a separate study for the targeted drug delivery to lung cancer A549 cells which express high levels of MUC1 [73]. The gene discussed is MUC1; the disease is lung cancer.